FLT3 and acute myeloid leukemia: Furthermore, a randomized trial evaluating the additional effect of gilteritinib on midostaurin in combination with intensive chemotherapy in untreated patients (≤65 years) with FLT3-mutated AML has been initiated (NCT03836209).